<DOC>
	<DOCNO>NCT02223832</DOCNO>
	<brief_summary>This study evaluate relative pharmacokinetic property tolerability safety ACT-128800 Japanese Caucasian healthy male female subject single-dose administration .</brief_summary>
	<brief_title>Study Evaluate Pharmacokinetics , Tolerability , Safety ACT-128800 Japanese Caucasian Healthy Male Female Subjects</brief_title>
	<detailed_description>10 Japanese 10 Caucasian healthy male female subject one one male female ratio include study . Japanese Caucasian subject match body weight .</detailed_description>
	<criteria>Signed informed consent prior studymandated procedure . Japanese Caucasian . ( Japanese subject : parent subject Japanese [ bear Japan ] . Caucasian subject : parent subject Caucasian ) . Body mass index 18 28 kg/m^2 , inclusive . Women childbearing potential : Women childbearing potential must negative serum pregnancy test screen negative urine pregnancy test prior drug intake Day 1 ; use reliable method contraception continue contraception duration study least 2 month study drug intake . In addition , partner must use condom . Systolic blood pressure 100145 mmHg , diastolic blood pressure 5090 mmHg , heart rate ( HR ) 5095 beat per minute ( inclusive ) . 12lead electrocardiogram without clinically relevant abnormality screen . Hematology clinical chemistry result deviate normal range clinically relevant extent screening . Negative result urine drug screen screen . Ability communicate well Investigator ( necessary help interpreter ) understand comply requirement study . Electrocardiograph PQ/PR interval ( time interval begin P wave begin QRS complex ) &gt; 200 millisecond screen . Nursing woman . History asthma chronic obstructive pulmonary disease . Known hypersensitivity excipients drug formulation . Treatment another investigational drug within 3 month prior screen . Excessive caffeine consumption , define &gt; 800 mg per day screening . History clinical evidence disease and/or existence surgical medical condition might interfere absorption , distribution , metabolism excretion study drug . Any cardiac condition illness , include ECG abnormality , potential increase cardiac risk subject . Smoking within last month prior screen . Any immunosuppressive treatment within 6 week study drug administration . Previous treatment prescribe overthecounter medication within 2 week prior screen . Loss 250 mL blood within 3 month prior screen . Lymphopenia ( &lt; 1,000 lymphocytes/Î¼L ) . Viral , fungal , bacterial protozoal infection within 4 week study drug administration . Positive result hepatitis serology , except vaccinated subject , screen . Positive result human immunodeficiency vrus serology screen . Legal incapacity limit legal capacity screening . History alcoholism drug abuse . Any circumstance condition , , opinion investigator , may affect full participation study compliance protocol .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>ACT-128800</keyword>
	<keyword>Safety</keyword>
	<keyword>Tolerability</keyword>
	<keyword>Pharmacokinetics</keyword>
</DOC>